ASTCT Talks

Епизоди

• Navigating the Dynamic Landscape of Stem Cell Transplantation 22.06.2026 11мин

  In a cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the impact of omidubicel-onlv (Omisirge) on patient outcomes, current research on reducing the risk of graft-vs-host disease (GVHD) among transplantation recipients, and strategies for providing effective prophylaxis during treatment, among other topics.
• ASTCT Talks: GVHD in Pediatrics: Acute and Chronic Risk 18.06.2026 28мин

  In this episode of ASTCT Talks, host Dr. Corey Cutler, MD, from Dana-Farber Cancer Institute, is joined by Dr. Pooja Khandelwal, MD (Cincinnati Children’s Hospital), Dr. Ben Watkins, MD (Tulane University), and Dr. Kenneth Cooke, MD (Johns Hopkins University) for an in-depth discussion on evolving strategies to prevent graft-versus-host disease (GVHD) in pediatric transplant.The conversation explores how leading centers are approaching GVHD prophylaxis across a range of clinical scenarios, with a focus on improving both acute and chronic GVHD outcomes. Experts compare platform-based approaches — including post-transplant cyclophosphamide, calcineurin inhibitor–based regimens, abatacept, and graft manipulation — and discuss how these strategies influence long-term transplant success.Key topics include:Current approaches to reducing acute and chronic GVHD in pediatric patients.Tradeoffs between prevention platforms, including immune reconstitution and infection risk.Emerging data on novel strategies, such as vitamin A and extended co-stimulation blockade.The role of GVHD-free survival as a key endpoint in transplant outcomes.Ongoing challenges and unmet needs in preventing chronic GVHD.While advances in prophylaxis are helping to reduce GVHD incidence, chronic GVHD remains a significant clinical challenge, underscoring the importance of continued innovation across the prevention-treatment continuum.This episode was supported by an educational grant fromIncyte.
• Podcast: Unraveling Key Hematologic Oncology Developments at ASCO 2026 09.06.2026 24мин

  In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations.
• Podcast: Exploring and Managing Gastrointestinal-Related CAR T-Cell Lymphomas 02.06.2026 19мин

  In a special cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, host Rahul Banerjee, MD, FACP, spoke with colleague Hitomi Hosoya, MD, PhD, about a study she and coauthors published in Blood. In their study, Hosoya and colleagues assessed the underlying mechanisms of chimeric antigen receptor (CAR) T-cell–related lymphomas developing in the gastrointestinal (GI) tract. The study focused on a particular case involving a 50-year-old patient with relapsed/refractory multiple myeloma who developed T-cell lymphoma after receiving cellular therapy in the seventh-line setting. Listen below or via your favorite podcast platform.
• ASTCT Talks: Gene Therapy Today and Tomorrow 20.05.2026 19мин

  Gene therapy is changing how clinicians care for patients with rare and genetic diseases, with more therapies moving from research into clinical use. In this episode, Dr. Nirali Shah is joined by Dr. Christy Duncan and Dr. Sung‑Yun Pai to talk through recent progress in the field and what it actually takes to deliver these treatments at the patient level.The discussion draws on their experience in transplant and genetic disease, covering both scientific advances and the operational challenges that come with implementing gene therapy — especially in complex and resource‑intensive settings. Tune in for a conversation that covers:Recent developments in gene therapy, including in vivo approaches and newly approved treatmentsBarriers to broader use, including access, equity, and long-term monitoringWhat centers need to consider when building a gene therapy program, from workflows to team coordinationWhere things may be heading, including more individualized therapies and efforts to expand availabilityListen to the episode below or on your favorite app. Subscribe to ASTCT Talks and share this episode with your colleagues to keep the conversation going.
• Treatment Options for cGVHD: Adult vs. Pediatric Perspectives 31.03.2026 29мин

  In this episode of ASTCT Talks, host Corey Cutler, MD of Dana-Farber Cancer Institute and Harvard University sits down with Nosha Farhadfar, MD, medical director of research for Sarah Cannon Research Institute’s transplant and cellular therapy program at Methodist Healthcare, and Pooja Khandelwal, MD, an associate professor within the division of bone marrow transplantation at Cincinnati Children’s Hospital Medical Center, to discuss adult and pediatric treatment perspectives for cGVHD.Tune in for a conversation that covers:Adult and pediatric cGVHD treatment approaches,including frontline choices and the selection and effectiveness of medications.Expert practice experiences for use in cGVHD treatment.New therapeutics the experts are looking forward to in cGVHD treatment. This episode was made possible thanks to a grant from Incyte.
• Best Practice Considerations for Infection Prevention and Management Post-CAR T 13.01.2026 36мин

  In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD(The University of Texas MD Anderson Cancer Center; Pharmacy SIG Immediate Past-Chair), sits down with Zainab Shahid, MD (Memorial Sloan Kettering Cancer Center; ID SIG Chair), and Gabriela Maron, MD (St. Jude Children’s ResearchHospital). As coauthors of the ASTCT Practice Guidelines, "American Society for Transplantation and Cellular Therapy Best Practice Considerations for the Prevention and Management of Infections After Chimeric Antigen Receptor T-Cell Therapy for Hematological Malignancies," recently published in Transplantation and Cellular Therapy, they discuss the implementation of critical strategies for safeguarding CAR T recipients.The conversation explores the nuances of the manuscript,providing a practical perspective on translating these consensus recommendations into clinical operations.Assessing the Burden of Immunosuppression: Evaluating the cumulative risk factors that predispose CAR T recipients to infection, including heavy pretreatment and the effects of lymphodepletion.Prophylaxis Optimization: Critical considerations regarding the timing, selection, and duration of antimicrobial regimens in the post-CAR T setting.Managing Hypogammaglobulinemia: A pragmatic look at IVIG replacement strategies, balancing emerging clinical evidence with institutional protocols and global product shortages.Addressing Evidence Gaps: Insider insights into the expert panel’s deliberations on "grey areas," such as the management of CMV reactivation and optimal post-therapy vaccination schedules.The Pediatric-Adult Continuum: Ensuring that prevention and management strategies are robust and applicable across the full age spectrum of CAR-T recipients.This episode provides essential context for cliniciansseeking to move beyond the published guidelines and operationalize these bestpractices with greater precision and confidence.Thank you to Johnson & Johnson and Legend Biotech forsupporting this episode.
• LIVE From ASH: Multiple Myeloma Treatment Redefined by Bispecific Antibodies and T-Cell Therapies 06.01.2026 27мин

  In a special cobranded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD, FACP, a physician-researcher who specializes in multiple myeloma at Fred Hutchinson Cancer Center, and Brooke Adams, PharmD, BCOP, a clinical pharmacist and transplant specialist at Orlando Health, break down practice‑changing data in multiple myeloma from the ASH Annual Meeting.The experts focus on bispecific antibodies and BCMA CAR T-cell therapies and close the discussion by reflecting on how data is redefining the treatment paradigm in multiple myeloma, raising possibilities of deep MRD negativity, treatment de-escalation, and prolonged drug holidays. Listen below or via your favorite podcast platform.
• What Clinicians Need to Know About Chronic GVHD and Immunity 16.12.2025 20мин

  In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, host Dr. Corey Cutler, MD, from Dana-Farber Cancer Institute, sits down with Dr. Sanjeet Singh Dadwal, MD, chief of infectious diseases at City of Hope, to explore a critical aspect of chronic graft-versus-host disease (GVHD): immune dysfunction and infection risk.The discussion highlights:• How chronic GVHD independently contributes to immune deficits and infection susceptibility.• Infectious risks associated with FDA-approved therapies for chronic GVHD.• Common infections in this population and why vigilance matters.• Practical guidance on prophylaxis strategies, vaccination timing, and navigating real-world challenges like food safety.This episode offers actionable insights for clinicians managing infection prevention and survivorship care in patients with chronic GVHD.Read “Infectious Disease Considerations in Chronic Graft-versus-Host Disease and Transplantation Survivors,” included in the 2024 GVHD Supplement collection published by Transplantation and Cellular Therapy.
• Pulmonary Manifestations of Chronic GVHD 16.12.2025 23мин

  In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler, from Dana-Farber Cancer Institute, and Dr. Guang-Shing Cheng, from the University of Washington and Fred Hutchinson Cancer Center, discuss how to identify and manage non-infectious lung complications following allogeneic transplant. From differentiating infection versus inflammation to managing conditions like organizing pneumonia (OP), this conversation offers practical insights for clinicians.For a deeper dive, explore Dr. Cheng’s many publications on pulmonary topics in the Journal of Transplantation and Cellular Therapy. Additionally, read the article “Late-Onset Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation” by Harris et al. shared in a September 2024 GVHD Supplement collection by the journal.
• Tackling Cognitive Challenges in Survivorship Care 02.12.2025 24мин

  In this episode of ASTCT Talks, host Christina Ferraro, nurse practitioner from the Cleveland Clinic, sits down with Vanessa Kennedy, MD, from Stanford University, to address a critical aspect of survivorship: cognitive health, including issues like brain fog, memory lapses and reduced executive function.The discussion highlights:New ASTCT consensus guidelines on cognitive assessment.Practical strategies for operationalizing cognitive screening in busy clinical settings. How factors like anxiety, depression, sleep and polypharmacy influence cognition — and why addressing these is critical. Emerging interventions, from cognitive rehabilitation to surprisingly effective options like jigsaw puzzles.This episode offers actionable insights into supporting cognitive function and quality of life in survivorship care.
• Titans of Transplant: Innovations in CAR T Cell Therapy 24.10.2025 41мин

  In this episode of ASTCT’s Titans of Transplant series, Dr. Taha Al-Juhaishi welcomes Dr. Sattva Neelapu of MD Anderson Cancer Center for a deep and insightful conversation on the evolution, challenges and future of CAR T therapy.From the groundbreaking ZUMA-1 trial to today’s expandinglandscape of commercial CAR T products, Dr. Neelapu shares pivotal clinical experiences, lessons learned in toxicity management and reflections on mentorship and innovation. This episode offers a look at the progress made, the barriers that remain and the opportunities ahead for the next generation of leaders in cellular therapy.
• Pharmacist Takeover: BCMA Bispecifics and CAR T-Cell Therapy 16.10.2025 37мин

  In this episode of ASTCT Talks, we're excited to share a special feature from the Pharmacy Focus: Oncology Edition podcast in honor of American Pharmacists Month, featuring members of ASTCT Pharmacy SIG. Expert pharmacists share key insights on BCMA bispecifics, CAR T-cell therapies, and other cellular treatments for multiple myeloma. Moderated by Ryan Shaw, PharmD, of the University of North Carolina at Chapel Hill, the discussion features Sara Ann Scott, PharmD, of Emory Winship Cancer Institute, and Kelley Julian, PharmD, of the University of Utah Huntsman Cancer Institute. Together, they explore treatment sequencing strategies for cellular therapies, with a focus on ciltacabtagene autoleucel and idecabtagene vicleucel.
• Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors 09.10.2025 26мин

  A panel of oncology pharmacists discusses the role oflifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors. Featuring Brooke Adams, PharmD, BCOP Natalie Brumwell, PharmD, BCOP Bryant A. Clemons, PharmD, BCOP In a special co-branded episode between Oncology On theGo, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The panel included Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at the Orlando Health Cancer Institute in Orlando, Florida; Natalie Brumwell, PharmD, BCOP, a board-certified oncology pharmacist specializing in cellular therapy at Memorial Sloan Kettering Cancer Center in New York, New York; and Bryant A. Clemons, PharmD, a board-certified oncology pharmacist specializing in hematology, blood and marrow transplantation, and cellular therapy at the University of Kentucky’s Markey Cancer Center in Lexington, Kentucky. The discussion focused on the use of the first commercially available tumor-infiltrating lymphocytes (TILs) for patients with unresectable or metastatic melanoma, lifileucel (Amtagvi), which the FDA granted accelerated approval status to in February 2024.1 The panelists first reviewed supporting data from the phase 2 C-144-01 trial (NCT02360579), in which lifileucel demonstrated an objective response rate of 31.5% (95% CI, 21.1%-43.4%), and a median duration of response that was not reached (NR; 95% CI, 4.1 months-NR) at the time of the approval. Additionally, the group highlighted considerations for dosinginterleukin-2 (IL-2), including management of toxicities and when to hold or discontinue further doses. Following a thorough breakdown of the proper conditions for using lifileucel in melanoma, the panelists concluded by discussing how to build upon an “exciting time for cellular therapy in solid tumors.” As part of optimizing the dosing of lifileucel and other cellular therapies in these patient populations, the experts exchanged ideas on how practices can collaborate across institutions and departments to expand access to novel treatments while helping providers develop comfort in administering these agents. Reference FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. News release. FDA. February 16, 2024. Accessed September 30, 2025. https://tinyurl.com/2kweca6x 
• Cord Blood Transplantation: Past, Present and Future Innovations 02.10.2025 33мин

  In this episode of ASTCT Talks, Dr. Taha Al-Juhaishi is joined by Dr. Filippo Milano, director of the Cord Blood Transplant Program at Fred Hutch, for a wide-ranging conversation on the evolving role of umbilical cord blood transplantation. From its historical milestones to emerging clinical strategies, Dr. Milano shares insights drawn from decades of research, practice and mentorship. The discussion explores the unique biological advantages of cord blood, including its potent graft-versus-leukemia effect and low incidence of chronic GVHD. Dr. Milano outlines ideal patient profiles, unit selection criteria and conditioning regimens, while addressing challenges like engraftment delays and infection risk. As the field looks ahead, Dr. Milano reflects on theimportance of inclusivity, scientific rigor and mentorship to reengage transplant centers and inspire the next generation of clinicians. Whether as a stand-alone therapy or part of a hybrid platform, cord blood transplantation continues to offer hope for patients with high-risk disease and limited donor options.
• Managing Mental Health in Chronic GVHD 12.09.2025 30мин

  In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler is joined by psychiatrist and physician-scientist Dr. Hermioni Amonoo to explore the psychological complexities faced by patients undergoing stem cell transplantation and living with chronic GVHD. Drawing from her research and clinical experience, Dr. Amonoo introduces a biobehavioral framework that integrates biological, psychological and social factors.This episode offers practical insights and compassionate strategies for improving psychological well-being in transplant patients, highlighting the importance of interdisciplinary care.For more information, read the article “A Biobehavioral Perspective on Caring for Allogeneic Hematopoietic Stem Cell Transplant Survivors with Graft-Versus-Host Disease” by Lahijani et al. shared in a September 2024 GVHD Supplement collection by the journal.
• Physician-Patient Communication in the Post-Transplant Setting 05.08.2025 27мин

  In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler sits down with Dr. Ana Barata to discuss the critical role of physician-patient communication in GVHD and stem cell transplantation. Together, they unpack the complex emotional and psychological landscape facing transplant survivors and the communication barriers that often go unspoken. Dr. Barata shares insights into the challenges faced by both patients and providers, ranging from unspoken anxiety and cognitive dysfunction to hesitations around discussing complementary therapies. This episode offers a look at how better communication can transform the transplant experience, making space for shared decision-making, emotional support and truly patient-centered care. For more information, read the article “Patient and Physician Communication in the Allogeneic Transplantation Setting: Challenges and Potential Solutions” by Barata et al. shared in a September 2024 GVHD Supplement collection by the journal.
• Delayed Neurotoxicity With Car-T Therapy in Myeloma: What Clinicians Need To Know 17.07.2025 21мин

  In this episode of ASTCT Talks, Dr. Rahul Banerjee sits down with Dr. Kenneth Lim and Dr. Yi Lin of Mayo Clinic to discuss a critical and emerging topic in CAR T-cell therapy: delayed neurotoxicities following cilta-cel treatment in multiple myeloma. They break down the clinical features of nerve palsies and Parkinsonism-like symptoms, share diagnostic and treatment strategies and explore emerging predictive markers like absolute lymphocyte count. Given that cilta-cel is increasingly being used in second-line myeloma treatment and is even being studied in first-line treatment to replace stem cell transplantation, this conversation is a timely and insightful look at improving patient outcomes in CAR T-cell therapy.
• Titans of Transplant: Dr. Daniel Weisdorf 25.06.2025 1ч 6мин

  In the next installment of ASTCT's Titans of Transplant series, Dr. Shernan Holtan sits down with Dr. Daniel Weisdorf—renowned leader, mentor and pioneer in cellular therapy and transplantation—for a reflective and engaging conversation on the evolution of the field. From the early days of sibling-only donors and bone marrow harvests to today’s innovations in GVHD prophylaxis and cord blood transplantation, Dr. Weisdorf shares personal anecdotes, pivotal clinical insights and lessons in mentorship, writing and research. Together, they explore the milestones, challenges and future directions in transplant and cellular therapy—offering a powerful perspective on what it means to make a lasting impact in patient care and scientific progress.
• CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025 16.06.2025 35мин

  An expert panel highlights key presentations in multiplemyeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types.Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University HealthStephenson Cancer Center and serves as an ambassador for ASCO.The group highlighted several late-breaking abstracts,plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following:Phase 1b/2 CARTITUDE-1 trial (NCT03548207,NCT05201781)1Long-term follow-up showed that approximately one-third(33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti). An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas.With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-notevaluable [NE]). Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use2Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma.Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings.Phase 1b/2 NEXICART-2 trial (NCT06097832)3Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options.Among 12 patients who received the agent at 450x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively. With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred.References1.     Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.75072.     Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-celllymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.70233.     Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508.doi:10.1200/JCO.2025.43.16_suppl.7508